Novel strategies for the treatment of small-cell lung carcinoma

Nature Reviews Clinical Oncology

Volumn 8, Issue 10, 2011, Pages 611-619

  William, William N ^a   Glisson, Bonnie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; IMATINIB; IRINOTECAN; MARIMASTAT; NAVELBINE; OBLIMERSEN; PACLITAXEL; PICOPLATIN; PLACEBO; SORAFENIB; TANOMASTAT; TEMSIROLIMUS; TENIPOSIDE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VINCRISTINE;

BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

EID: 80053562740     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.90     Document Type: Review

References (121)

1. Govindan, R., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 24, 4539-4544 (2006). (Pubitemid 46630948)
2. Spiro, S. G., et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J. Clin. Oncol. 24, 3823-3830 (2006). (Pubitemid 46630728)
3. Fried, D. B., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J. Clin. Oncol. 22, 4837-4845 (2004).
4. De Ruysscher, D., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J. Clin. Oncol. 24, 1057-1063 (2006). (Pubitemid 46638802)
5. Pijls-Johannesma, M. C., De Ruysscher, D., Lambin, P., Rutten, I. & Vansteenkiste, J. F. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database of Systematic Reviews, Issue 4. Art.: CD004700. doi:10.1002/14651858.CD004700.pub2 (2005).
6. De Ruysscher, D., et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann. Oncol. 17, 543-552 (2006).
7. Huncharek, M. & McGarry, R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9, 665-672 (2004). (Pubitemid 39549328)
8. Turrisi, A. T. 3rd, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340, 265-271 (1999).
9. Aupérin, A., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341, 476-484 (1999). (Pubitemid 29372887)
10. Slotman, B., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J. Med. 357, 664-672 (2007). (Pubitemid 47267236)
11. Oze, I., et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 4, e7835 (2009).
12. Noda, K., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85-91 (2002). (Pubitemid 34438898)
13. Lara, P. N. Jr, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27, 2530-2535 (2009).
14. Ciuleanu, T., et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a7002 (2010).
15. Groen, H. J., et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J. Clin. Oncol. 17, 927-932 (1999). (Pubitemid 29109325)
16. Smyth, J. F., et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur. J. Cancer 30A, 1058-1060 (1994).
17. Smit, E. F., et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br. J. Cancer 77, 347-351 (1998). (Pubitemid 28029555)
18. Masters, G. A., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J. Clin. Oncol. 21, 1550-1555 (2003). (Pubitemid 46594109)
19. Furuse, K., et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 53, 169-172 (1996). (Pubitemid 26087927)
20. Masuda, N., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10, 1225-1229 (1992).
21. von Pawel, J., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17, 658-667 (1999). (Pubitemid 29075255)
22. OBrien, M. E., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol. 24, 5441-5447 (2006).
23. Eckardt, J. R., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086-2092 (2007). (Pubitemid 46972795)
24. Holford, J., Sharp, S. Y., Murrer, B. A., Abrams, M. & Kelland, L. R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer 77, 366-373 (1998). (Pubitemid 28044038)
25. Holford, J., et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 13, 1-18 (1998). (Pubitemid 28045535)
26. Holford, J., Beale, P. J., Boxall, F. E., Sharp, S. Y. & Kelland, L. R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur. J. Cancer 36, 1984-1990 (2000).
27. Mistry, P., Kelland, L. R., Abel, G., Sidhar, S. & Harrap, K. R. The relationships between glutathione, glutathione-S.-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer 64, 215-220 (1991).
28. Treat, J., et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur. J. Cancer 38, S13-S18 (2002). (Pubitemid 41127955)
29. Eckardt, J. R., et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J. Clin. Oncol. 27, 2046-2051 (2009).
30. Giaccone, G., Donadio, M., Bonardi, G., Testore, F. & Calciati, A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J. Clin. Oncol. 6, 1264-1270 (1988).
31. Batist, G., et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann. Intern. Med. 98, 472-474 (1983). (Pubitemid 13116615)
32. Postmus, P. E., et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur. J. Cancer Clin. Oncol. 23, 1409-1411 (1987). (Pubitemid 18006732)
33. Giaccone, G., Ferrati, P., Donadio, M., Testore, F. & Calciati, A. Reinduction chemotherapy in small cell lung cancer. Eur. J. Cancer Clin. Oncol. 23, 1697-1699 (1987). (Pubitemid 18044647)
34. Vincent, M., Evans, B. & Smith, I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother. Pharmacol. 21, 45-48 (1988). (Pubitemid 18050480)
35. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007). (Pubitemid 47106628)
36. Kawamura-Akiyama, Y., et al. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer 38, 43-50 (2002). (Pubitemid 35299991)
37. Tang, C. H., Parham, C., Shocron, E., McMahon, G. & Patel, N. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother. Pharmacol. 67, 1389-1400 (2011).
38. Sozzi, G., et al. Chromosomal abnormalities in a primary small cell lung cancer. Cancer Genet. Cytogenet. 27, 45-50 (1987). (Pubitemid 17100289)
39. Miura, I., Graziano, S. L., Cheng, J. Q., Doyle, L. A. & Testa, J. R. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res. 52, 1322-1328 (1992).
40. De Fusco, P. A., et al. Cytogenetic studies in 11 patients with small cell carcinoma of the lung. Mayo Clin. Proc. 64, 168-176 (1989). (Pubitemid 19080933)
41. Whang-Peng, J., et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 215, 181-182 (1982). (Pubitemid 12178106)
42. Brauch, H., et al. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N. Engl. J. Med. 317, 1109-1113 (1987). (Pubitemid 17156740)
43. Kok, K., et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330, 578-581 (1987). (Pubitemid 17164357)
44. Naylor, S. L., Johnson, B. E., Minna, J. D. & Sakaguchi, A. Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329, 451-454 (1987). (Pubitemid 17128316)
45. Ohta, M., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587-597 (1996). (Pubitemid 26071739)
46. Roche, J., et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12, 1289-1297 (1996). (Pubitemid 26128926)
47. Sekido, Y., et al. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc. Natl Acad. Sci. USA 93, 4120-4125 (1996). (Pubitemid 26146727)
48. Tomizawa, Y., et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc. Natl Acad. Sci. USA 98, 13954-13959 (2001). (Pubitemid 33116005)
49. Latif, F., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993). (Pubitemid 23231974)
50. Dammann, R., et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25, 315-319 (2000). (Pubitemid 30437320)
51. Virmani, A. K., et al. Promoter methylation and silencing of the retinoic acid receptor gene in lung carcinomas. J. Natl Cancer Inst. 92, 1303-1307 (2000). (Pubitemid 30660589)
52. Burbee, D. G., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst. 93, 691-9 (2001). (Pubitemid 32492810)
53. Levin, N. A., Brzoska, P. M., Warnock, M. L., Gray, J. W. & Christman, M. F. Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosomes Cancer 13, 175-185 (1995).
54. Petersen, I., et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 57, 2331-2335 (1997). (Pubitemid 27255883)
55. Ried, T., et al. Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res. 54, 1801-1806 (1994). (Pubitemid 24116190)
56. Voortman, J., et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc. Natl Acad. Sci. USA 107, 13040-13045 (2010).
57. Pleasance, E. D., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
58. Lubin, J. H., et al. Cigarette smoking and cancer risk: modeling total exposure and intensity. Am. J. Epidemiol. 166, 479-489 (2007). (Pubitemid 47216789)
59. Olejniczak, E. T., et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol. Cancer Res. 5, 331-339 (2007). (Pubitemid 46706995)
60. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
61. Meyerson, M. & Carbone, D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J. Clin. Oncol. 23, 3219-3226 (2005). (Pubitemid 46211346)
62. Anbazhagan, R., et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 59, 5119-5122 (1999). (Pubitemid 29503970)
63. Bhattacharjee, A., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790-13795 (2001). (Pubitemid 33115977)
64. Bangur, C. S., et al. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 21, 3814-3825 (2002). (Pubitemid 34620545)
65. Taniwaki, M., et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int. J. Oncol. 29, 567-575 (2006).
66. Virtanen, C., et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc. Natl Acad. Sci. USA 99, 12357-12362 (2002).
67. Liu, H., Kho, A. T., Kohane, I. S. & Sun, Y. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med. 3, e232 (2006).
68. Jones, M. H., et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363, 775-781 (2004). (Pubitemid 38315167)
69. Cho, N. H., et al. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation. J. Proteome Res. 5, 643-650 (2006). (Pubitemid 43364105)
70. Miko, E., et al. Differentially expressed microRNAs in small cell lung cancer. Exp. Lung Res. 35, 646-664 (2009).
71. Guo, L., et al. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur. J. Cancer 46, 1692-1702 (2010).
72. Janne, P. A., et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95, 1528-1538 (2002).
73. Sundstrom, S., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J. Clin. Oncol. 20, 4665-4672 (2002). (Pubitemid 36025283)
74. Chute, J. P., Chen, T., Feigal, E., Simon, R. & Johnson, B. E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol. 17, 1794-1801 (1999). (Pubitemid 29269249)
75. Pujol, J. L., Carestia, L. & Daures, J. P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br. J. Cancer 83, 8-15 (2000).
76. Hanna, N., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038-2043 (2006). (Pubitemid 46622112)
77. Onoda, S., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J. Clin. Oncol. 24, 5448-5453 (2006). (Pubitemid 46623179)
78. Jotte, R., et al. Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a8028 (2009).
79. Chiappori, A., et al. Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT) [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a3012 (2007).
80. Rudin, C. M., et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J. Clin. Oncol. 26, 870-876 (2008). (Pubitemid 351398078)
81. Dy, G. K., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. 16, 1811-1816 (2005). (Pubitemid 41631245)
82. Krug, L. M., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103, 2128-2131 (2005). (Pubitemid 40605121)
83. Pandya, K. J., et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J. Thorac. Oncol. 2, 1036-1041 (2007). (Pubitemid 350059580)
84. Tarhini, A., et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin. Cancer Res. 16, 5900-5907.
85. Pujol, J. L., et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J. Clin. Oncol. 25, 3945-3951 (2007).
86. Lee, S. M., et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J. Natl Cancer Inst. 101, 1049-1057 (2009).
87. Ready, N., et al. CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a7563 (2007).
88. Sandler, A., Szwaric, S., Dowlati, A., Moore, D. F. & Schiller, J. H. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a7564 (2007).
89. Spigel, D. R., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J. Clin. Oncol. 28, 43-48 (2010).
90. Gitlitz, B. J., et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J. Thorac. Oncol. 5, 1835-1840 (2010).
91. Arnold, A. M., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J. Clin. Oncol. 25, 4278-4284 (2007). (Pubitemid 47548568)
92. Ramalingam, S. S., et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J. Thorac. Oncol. 5, 1279-1284 (2010).
93. Heymach, J., et al. Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC) [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a7050 (2010).
94. Shepherd, F. A., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20, 4434-4439 (2002). (Pubitemid 35334754)
95. Rigas, J. R., et al. Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI) [abstract 0107]. Lung Cancer 41, S34 (2003).
96. Gandhi, L., et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109, 924-932 (2007). (Pubitemid 46333534)
97. Giaccone, G., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23, 6854-6864 (2005).
98. Heymach, J. V., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann. Oncol. 15, 1187-1193 (2004). (Pubitemid 39199305)
99. Forgacs, E., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17, 1557-1565 (1998). (Pubitemid 28472760)
100. Yokomizo, A., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475-479 (1998). (Pubitemid 28395912)
101. Marinov, M., et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin. Cancer Res. 15, 1277-1287 (2009).
102. Tsurutani, J., West, K. A., Sayyah, J., Gills, J. J. & Dennis, P. A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 65, 8423-8432 (2005). (Pubitemid 41330609)
103. Ioannou, M., et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 187, 321-329 (2009).
104. Fontanini, G., et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer 86, 558-563 (2002). (Pubitemid 34185092)
105. Lucchi, M., et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. Cardiothorac. Surg. 21, 1105-1110 (2002).
106. Ma, P. C., et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br. J. Cancer 97, 368-377 (2007). (Pubitemid 47196754)
107. Takigawa, N., Segawa, Y., Maeda, Y., Takata, I. & Fujimoto, N. Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. Lung Cancer 17, 211-218 (1997). (Pubitemid 27304301)
108. Bharti, A., et al. Haptoglobin ?-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 24, 1031-1038 (2004). (Pubitemid 38624933)
109. Maulik, G., et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8, 620-627 (2002). (Pubitemid 34193985)
110. Puri, N., et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-3534 (2007). (Pubitemid 46762132)
111. Ma, P. C., et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63, 6272-6281 (2003). (Pubitemid 37255174)
112. Maulik, G., et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J. Cell Mol. Med. 6, 539-53 (2002). (Pubitemid 44149770)
113. Reeve, J. G., Payne, J. A. & Bleehen, N. M. Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br. J. Cancer 61, 727-731 (1990). (Pubitemid 20151340)
114. Minuto, F., et al. Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors. Cancer Res. 46, 985-988 (1986). (Pubitemid 16145468)
115. Yeh, J., Litz, J., Hauck, P., Ludwig, D. L. & Krystal, G. W. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 60, 166-74 (2008). (Pubitemid 351609143)
116. Warshamana-Greene, G. S., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res. 11, 1563-1571 (2005). (Pubitemid 40315241)
117. Lee, C. T., et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 56, 3038-3041 (1996).
118. Watkins, D. N., et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313-317 (2003). (Pubitemid 36378358)
119. Vestergaard, J., et al. Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52, 281-290 (2006). (Pubitemid 43674545)
120. Crisanti, M. C., et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol. Cancer Ther. 8, 2221-2231 (2009).
121. Hubaux, R., et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur. J. Cancer 46, 1724-1734 (2010).